Cardiovascular actions of beta-phenylethylamine.

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Neuroscience

Background:

• Beta-phenylethylamine (PEA) is an endogenous trace amine found in the brain.
• Its physiological roles and cardiovascular effects are not fully understood.
• Previous studies suggest PEA may interact with adrenergic systems.

Purpose of the Study:

• To investigate the cardiovascular and cardiac effects of beta-phenylethylamine in vivo.
• To determine the mechanisms underlying these effects, particularly the involvement of adrenergic receptors and norepinephrine release.

Main Methods:

• Experiments were conducted on chloralose-anesthetized dogs.
• Measurements included mean aortic blood pressure, total peripheral vascular resistance, and left ventricular contractility (dP/dt and (dP/dt)/P).
• The effects of beta-phenylethylamine were assessed alone and after pretreatment with phentolamine (alpha-blocker), propranolol (beta-blocker), and desipramine (norepinephrine reuptake inhibitor).

Main Results:

• Beta-phenylethylamine significantly increased aortic blood pressure, peripheral vascular resistance, and left ventricular contractility.
• Phentolamine attenuated the pressor and vasoconstrictor effects, while propranolol abolished the positive inotropic effects.
• Desipramine completely blocked both cardiac and vascular actions of beta-phenylethylamine.

Conclusions:

• Beta-phenylethylamine exerts significant positive inotropic and vasoconstrictory effects.
• These actions are mediated primarily through the release of endogenous norepinephrine from adrenergic nerve endings.
• The findings highlight the role of beta-phenylethylamine in modulating cardiovascular function via the sympathetic nervous system.